ClinicalTrials.gg
Not yet recruitingNCT07608549Updated Nov 16, 2026

FLASH Pilot Phase 1 Safety Study

An interventional study of IntraOp Mobetron UHDR and Linac in Cutaneous Lymphoma, sponsored by Lesley A. Jarvis. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Lesley A. Jarvis · Not applicable, Interventional, and Device feasibility

How we know

Updated Nov 16, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this research trial is to study the safety of electron FLASH treatment for cutaneous lymphoma lesions. In addition, investigators will confirm the accuracy of dose and dose rate delivery of electron FLASH therapy using on-patient dosimetry measurements. Researchers will also determine the response rates of cutaneous lymphomas treated with a low radiation dose in a single fraction using electron UHDR treatments, followed by an assessment of radiation related skin toxicity.

02

Conditions studied

  • Cutaneous Lymphoma

Keywords

  • Conventional radiotherapy
  • Ultra-high dose rate (UDHR) radiotherapy
  • electron FLASH
03

In context

Lymphoma, T-Cell, Cutaneous

554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.

This study's planned enrollment of 10 is below the median of 35 across 405 interventional studies indexed under Lymphoma, T-Cell, Cutaneous.

Browse Lymphoma, T-Cell, Cutaneous studies →

Lead sponsor

This is the only study on the registry with Lesley A. Jarvis as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologic proof of cutaneous lymphoma.
  2. The cutaneous lymphoma is not planned to be treated with definitive, higher dose radiotherapy therapy.
  3. Participant is planned to receive a course of palliative radiation therapy at DHMC for a cutaneous lymphomas lesion located on an extremity (see appendix A) that can be encompassed in a field size no larger than 7.5 cm in diameter.
  4. No prior history of radiotherapy to the site of planned treatment.
  5. Patient agrees to discontinue topical therapy, including creams or chemotherapy agents, to the index lesion 4 weeks prior to the radiation treatment.
  6. Participant must be capable of providing or has an acceptable surrogate capable of providing consent on behalf of the participant.
  7. Adults at least 18 years of age
  8. performance status of \<3.
  9. Women of (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12-months and capable to become pregnant, must have a negative serum beta-HCG pregnancy test result within seven days prior to start of treatment.
  10. WOCBP who are sexually active must agree at study entry to use adequate methods of during treatment.

Exclusion criteria

Exclusion Criteria:

  1. Prior radiotherapy to the site of treatment.
  2. Index lesion UHDR treatment field is \<5cm from the field edge of a synchronously treated CONV lesion.
  3. Patient receiving prescribed hormonal therapies.
  4. Patients with known V5.0 grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection.
  5. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol.
  6. Patients with dementia or altered mental status that would preclude understanding and rendering of process.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Experimental arm treated with FLASH Radiation Therapy

    In participants with more than one cutaneous lesion requiring treatment, one lesion will be treated with electron FLASH therapy. The prescription dose will be 8 Gray (Gy) in 1 fraction.

    Device: IntraOp Mobetron UHDR

  • Active comparator
    Control arm treated with Conventional Radiation Therapy

    In participants who have more than one cutaneous lesion requiring treatment, the remainder of the lesions not treated with electron FLASH therapy will be treated with conventional electron treatment at the discretion of the treating radiation oncologist.

    Radiation: Linac

Interventions

  • DeviceIntraOp Mobetron UHDR

    The Mobetron UDHR System provides electrons for precision radiotherapy of lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The FLASH enabled Mobetron System is intended to deliver electron FLASH radiotherapy to participants with cutaneous lymphoma lesions located in extremities.

  • RadiationLinac

    Conventional radiotherapy

06

What researchers measure

Primary outcomes

  1. Incidences and grades of all grade-3-or-higher skin toxicities (according to CTCAE version 6.0) that are attributed to the electron FLASH treatment procedure [FLASH treatment safety and toxicity profile].

    To study the safety and characterize the toxicity profile of electron FLASH treatment, researchers will perform a clinical evaluation of all lesions treated and report data on the incidences and scores of all grade 3 or higher skin toxicities, measured according to the Common Terminology Criteria for Adverse Effects (CTCAE) version 6.0.

    Time frame: 5 years

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2029; primary completion for Dec 2030, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartEst.
Oct 31, 2029
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Safety and toxicity profile characterization of electron FLASH treatmentNow Incidences and grades of all grade-3-or-higher skin toxicities (according to CTCAE version 6.0) that are attributed to the electron FLASH treatment procedure [FLASH treatment safety and toxicity profile].Time frame: 5 years
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Safety and toxicity profile characterization of electron FLASH treatmentNow Incidences and grades of all grade-3-or-higher skin toxicities (according to CTCAE version 6.0) that are attributed to the electron FLASH treatment procedure [FLASH treatment safety and toxicity profile].Time frame: 5 years
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07608549
Lead sponsor
Lesley A. Jarvis
Collaborators
Dartmouth College
Responsible party
Lesley A. Jarvis (Principle Investigator, Dartmouth-Hitchcock Medical Center) — Sponsor-investigator
First posted
May 27, 2026
Start date
Oct 31, 2029 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Lesley A Jarvis, MD
Contact
lesley.a.jarvis@hitchcock.org
603-650-6600
Lesley A Jarvis, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion